PT-141 (Bremelanotide): The Complete Guide to the Libido Peptide (2026)

PT-141, known by its drug name bremelanotide, is a synthetic peptide that turns on sexual desire from the brain rather than the bloodstream, which is what makes it different from Viagra. It is also the rare research-world peptide that crossed over into a real, FDA-approved medicine: under the brand name Vyleesi, it is approved for premenopausal women with low sexual desire. The catch is that almost everything else people use it for, including men's libido and erectile dysfunction, sits outside that one approval as off-label or unapproved use.

If you have seen PT-141 sold as a libido injection, or heard of Vyleesi as the "female Viagra," this guide is the high-level map of the whole compound. It is also the most-used and only FDA-approved option among the best peptides for libido. We cover what it actually is, how its melanocortin mechanism works in the brain, what the clinical trials showed, its approved and off-label uses, the dosing that gets reported, side effects, the honest safety picture, its layered legal status, and how people obtain it. Each section is a clear overview; the deep-dive topics (a full dosing chart, the side-effect deep-dive, the comparison with Viagra and Melanotan 2, injection technique) point to dedicated guides so this page stays a clean hub.

Key Takeaways

• PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that works on melanocortin receptors in the brain to increase sexual desire; it is an active metabolite of the tanning peptide Melanotan 2, minus one chemical group (Wikipedia, "Bremelanotide", retrieved 2026-06-15).
• It is FDA-approved, but only for one use. In June 2019 the FDA approved it as Vyleesi (1.75 mg subcutaneous injection) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA, "VYLEESI Prescribing Information", 2019).
• It works on the brain, not the blood vessels. PT-141 activates the MC4 receptor and triggers dopamine release in brain areas tied to sexual motivation, unlike Viagra and Cialis, which act on blood flow (American Journal of Obstetrics & Gynecology / PMC, 2022, retrieved 2026-06-15).
• The female evidence is strong; the male evidence is early. Two Phase 3 trials (RECONNECT, ~1,247 women) met both desire and distress endpoints. Use in men for erectile dysfunction is off-label, supported only by earlier and ongoing Phase 2 studies (PMC, 2022; Urology Times, 2024).
• Nausea is the headline side effect. In trials, about 40% of women had nausea versus 1.3% on placebo, plus flushing (~20%) and headache (~11%); it also causes a transient rise in blood pressure (FDA label, 2019; PMC, 2022).
• Reported off-label/research doses cluster around 1 to 2 mg subcutaneously, taken on-demand about 45 minutes before activity. The approved Vyleesi dose is 1.75 mg, no more than once per 24 hours and no more than 8 times per month. The full ladder is a future dosing chart spoke.

What is PT-141?

PT-141 is a lab-made peptide, drug name bremelanotide, that works on the brain's sexual-desire system; it is the only peptide of its kind to become an FDA-approved medicine, sold as Vyleesi for low sexual desire in premenopausal women. It is a short, cyclic chain of amino acids, usually given as a subcutaneous injection. Most of the attention it gets outside that one approval comes from off-label and research use.

Chemically, bremelanotide is a cyclic heptapeptide lactam analog of alpha-melanocyte-stimulating hormone (alpha-MSH), with the molecular formula C50H68N14O10 and CAS number 189691-06-3 (Wikipedia, "Bremelanotide", retrieved 2026-06-15). It came directly out of the Melanotan tanning-peptide research: bremelanotide is an active metabolite of Melanotan 2 that lacks the C-terminal amide group, which shifts its effects away from tanning and toward the brain's sexual pathways. The intranasal version was developed first, but the FDA halted that program in 2007 after it caused blood-pressure increases in trial subjects, and development moved to the lower-exposure subcutaneous injection (Wikipedia, "Bremelanotide", retrieved 2026-06-15). If injectable peptides are new to you, start with our what are peptides and how peptides work guides.

The single most important fact about PT-141 is its split status: the exact drug, at the exact approved dose, for the exact approved population, is a real FDA-approved medicine. The injectable "research chemical" vials sold online, the doses used in men, and compounded versions are something else, legally and in terms of oversight. Everything in this guide should be read through that distinction.

Citation capsule. PT-141 (bremelanotide, brand name Vyleesi) is a synthetic cyclic heptapeptide lactam analog of alpha-MSH, sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, formula C50H68N14O10, CAS 189691-06-3, PubChem CID 9941379, DrugBank DB11653, ChEMBL ChEMBL2070241. It is a melanocortin-receptor agonist (mainly MC3R and MC4R), an active metabolite of Melanotan 2, developed by Palatin Technologies, and FDA-approved in June 2019 for HSDD in premenopausal women. Source: Wikipedia, "Bremelanotide," 2026; FDA VYLEESI Prescribing Information, 2019.

How does PT-141 work?

PT-141 works in the brain, not the bloodstream: it activates melanocortin receptors (mainly MC4R) in regions tied to sexual motivation, which triggers a dopamine signal that increases sexual desire. That central mechanism is the whole reason it is different from erectile-dysfunction pills, which act on blood flow. The brain pathway is well described in research, though the full picture is still being mapped.

In plain terms, drugs like Viagra and Cialis are "plumbing" drugs: they relax blood vessels so more blood reaches the genitals, but they do nothing for desire itself. PT-141 is a "wiring" drug: it acts upstream in the brain on the system that generates wanting sex in the first place. When bremelanotide binds the MC4 receptor, it activates a cascade that increases dopamine release in the medial preoptic area of the hypothalamus, the dopamine signal most tightly linked to sexual motivation in animal models (American Journal of Obstetrics & Gynecology / PMC, "Bremelanotide for Treatment of Female Hypoactive Sexual Desire", 2022, retrieved 2026-06-15). Because it acts centrally, it does not require sexual stimulation to be "primed" the way a blood-flow drug does, and it works without touching the vascular or hormonal systems.

Here is what each part of the mechanism contributes, in simple terms:

• MC4R (brain): the main target. Activation in the hypothalamus drives the dopamine signal behind sexual desire and arousal. This is the intended effect.
• MC3R (brain/body): also engaged; involved in energy balance and central signaling, part of the broader melanocortin activity.
• MC1R (skin): weakly hit. This is the tanning receptor that Melanotan 2 targets strongly; PT-141 touches it lightly, which is why repeated dosing can cause patchy skin darkening as a side effect.
• Dopamine release: the downstream output. The increase in dopamine in sexual-motivation circuits is the proposed reason desire goes up.

One detail that often gets lost: because the melanocortin system is shared between brain and body, the same central mechanism that drives the desired effect also drives the main side effects. The transient blood-pressure rise, the flushing, and the nausea all trace back to melanocortin signaling, not to a separate, unrelated toxicity. That is why you cannot fully separate "the effect" from "the side effects" by tweaking the route or the timing, they come from the same pharmacology, which is also why higher doses tend to add nausea and blood-pressure load rather than simply more benefit. It is also why the mechanism is genuinely sex-neutral at the receptor level: MC4R activation in the hypothalamus is not specific to female biology, which is the scientific basis for the off-label interest in men even though only the female indication has cleared trials.

The receptor-pharmacology deep dive (melanocortin selectivity, alpha-MSH biology, the dopamine circuitry) is its own topic. We keep it at overview level here and link out to how peptides work for the foundations.

What is PT-141 used for?

PT-141 has one FDA-approved use, treating low sexual desire (HSDD) in premenopausal women, and several off-label uses, most prominently men's low libido and erectile dysfunction, plus desire problems caused by antidepressants. Only the first is a reviewed, approved indication; the rest are off-label, supported by weaker or earlier evidence.

The approved use is specific and worth stating precisely: Vyleesi is for acquired, generalized HSDD in premenopausal women, meaning low desire that is distressing, that developed over time ("acquired"), and that is not limited to one situation ("generalized"), and that is not caused by another medical or psychiatric condition, relationship problems, or a medication (FDA, "VYLEESI Prescribing Information", 2019, retrieved 2026-06-15). Outside that lane, the most common off-label interest is in men: because the brain mechanism is not sex-specific, PT-141 is used off-label for erectile dysfunction (especially when Viagra-type drugs have not worked) and for low libido. There is also interest in using it for sexual dysfunction caused by SSRI antidepressants.

A quick overview of where PT-141 is used and how solid the evidence is:

A few words on why each off-label lane attracts interest, and how thin the evidence underneath it actually is. The strongest off-label case is men's erectile dysfunction, because there is at least one positive Phase 2 trial and a clear mechanistic rationale; the current Palatin Phase 2 combining bremelanotide with a PDE5 inhibitor is the study most likely to move that needle (Urology Times, 2024, retrieved 2026-06-15). Men's low libido (as opposed to mechanical ED) is a weaker case still, relying mostly on the shared brain mechanism and community reports rather than dedicated trials. The antidepressant angle is conceptually appealing, because SSRIs blunt sexual desire through brain pathways and PT-141 acts centrally rather than on blood flow, but it remains early-stage and investigational with no approved indication. And postmenopausal women, despite being an obvious population to ask about, fall outside the trial population entirely, the RECONNECT studies enrolled premenopausal women, so the approval and the safety data simply do not extend there.

Because each off-label use is really its own future spoke, we keep them brief here. The honest headline: PT-141 is a genuine approved medicine for one group of women, and a promising-but-unproven option for everyone else.

What did the clinical trials show?

The strongest evidence for PT-141 comes from two large Phase 3 trials in women (the RECONNECT program), which showed statistically significant improvements in both sexual desire and the distress that low desire causes; the evidence in men is earlier and smaller. This is why the approval is for women specifically, and why male use remains off-label.

The RECONNECT program was two identical Phase 3, randomized, double-blind, placebo-controlled trials in premenopausal women with HSDD, with a safety cohort of 1,247 women and an efficacy cohort of 1,202, dosing 1.75 mg of bremelanotide subcutaneously on an as-needed basis over 24 weeks (American Journal of Obstetrics & Gynecology / PMC, 2022, retrieved 2026-06-15). Both trials met their co-primary endpoints: improvement in the Female Sexual Function Index-desire domain (FSFI-D) and reduction in desire-related distress (the FSDS-DAO score).

Phase 3 (women, HSDD): the RECONNECT trials in detail

The two pivotal trials were labeled Study 301 and Study 302 and were published together by Kingsberg and colleagues in Obstetrics & Gynecology in 2019, the dataset the FDA relied on to approve Vyleesi. A total of 1,267 premenopausal women with acquired, generalized HSDD were randomized. On the desire endpoint (FSFI-D), bremelanotide produced statistically significant gains over placebo in both studies (Study 301: 0.30, P<.001; Study 302: 0.42, P<.001), and on the distress endpoint (FSDS-DAO Item 13) it produced significant reductions in both (Study 301: -0.37, P<.001; Study 302: -0.29, P=.005) (Kingsberg SA, et al., "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials," Obstetrics & Gynecology, 2019, PubMed 31599840, retrieved 2026-06-15). After the 24-week core trials, 684 women rolled into a 52-week open-label extension, which supported the longer-term safety and tolerability profile that underpins the on-demand approved use (Simon JA, Kingsberg SA, et al., "Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder," Obstetrics & Gynecology, 2019, retrieved 2026-06-15). It is worth being honest about the size of the average benefit: the desire gain of roughly a third of a point on a 5-point scale is statistically real but clinically modest, which is why the more meaningful signal is the paired drop in distress, and why a sizable share of women did not respond.

Phase 2 (men, ED): the earlier off-label evidence

The male evidence is older, smaller, and used the discontinued intranasal route. The landmark study randomized 342 men aged 28 to 59 with erectile dysfunction who had not responded to sildenafil to either 10 mg intranasal bremelanotide or placebo; about 34% on bremelanotide reported an erection sufficient for intercourse versus about 9% on placebo, with men dosing 45 minutes to 2 hours before activity (Diamond LE, Earle DC, Rosen RC, et al., "Salvage of sildenafil failures with bremelanotide," PubMed 18206919, retrieved 2026-06-15). That intranasal program was later halted over blood-pressure increases, and modern interest has shifted to the lower-exposure subcutaneous route: Palatin Technologies launched a new Phase 2 study in 2024 combining bremelanotide with a PDE5 inhibitor for ED (Urology Times, "Phase 2 study launches of bremelanotide plus a PDE5 inhibitor for erectile dysfunction", 2024, retrieved 2026-06-15). So men's use rests on a single positive Phase 2 trial from the old route plus a mechanism shared with the approved female indication, which is encouraging but a long way from the regulator-grade evidence behind Vyleesi.

How Vyleesi got approved (the regulatory pathway)

The RECONNECT data are what carried bremelanotide across the FDA finish line. On the strength of the two Phase 3 trials and the open-label extension, the FDA approved Vyleesi in June 2019 for acquired, generalized HSDD in premenopausal women, the second-ever drug approved for female HSDD after flibanserin (Addyi) in 2015 (Palatin Technologies, "FDA Approves New Drug Application for Vyleesi (bremelanotide injection)", 2019, retrieved 2026-06-15). The approval matters for reading every other claim about PT-141: it means an independent regulator reviewed real efficacy and safety data and accepted that bremelanotide works for one specific population at one specific dose. It does not mean the FDA blessed PT-141 in general. The label is narrow on purpose, it carves out exactly who the trials studied (premenopausal women), and it attaches the cardiovascular cautions and the once-per-24-hours, eight-per-month limits that came out of the safety data. Everything sold or used beyond that, including all male use and the research-chemical vials, sits outside what the regulator actually reviewed.

This is the practical takeaway from the trial evidence as a whole. PT-141 is one of the very few peptides in the wider "research peptide" conversation that has cleared the highest evidentiary bar for a single use, while remaining genuinely unproven for the uses many people are most curious about. Holding both of those facts at once is the honest way to read the science.

Our take: The honest way to read this is that PT-141 has real, regulator-grade evidence for one use and one population, and everything else rides on that mechanism being plausible plus smaller studies. The female desire data are solid. The male data are encouraging but early, which is exactly why men's use is off-label, not approved.

What doses of PT-141 do people use?

The FDA-approved dose is 1.75 mg injected under the skin, on-demand, at least 45 minutes before sexual activity, no more than once in 24 hours and no more than 8 times a month; off-label and research protocols commonly report 1 to 2 mg subcutaneously on a similar on-demand basis. The approved figure is anchored to a real label; the off-label figures are conventions, not validated dosing.

For the approved product, the label is precise: Vyleesi is dosed at 1.75 mg subcutaneously in the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose per 24 hours and no more than eight doses per month recommended (FDA, "VYLEESI Prescribing Information", 2019, retrieved 2026-06-15). In the off-label and research-peptide world, people most often report 1 to 2 mg subcutaneously, taken roughly 45 minutes to an hour before activity, with effects commonly described as starting within about an hour and lasting several hours. Many users start lower (for example 0.5 mg) to gauge nausea, then increase. We label the off-label numbers as a community convention because they are not an approved or dose-finding-validated regimen, and higher doses tend to mean more nausea, not necessarily more benefit. It is worth noting that the only formal male dosing data come from the discontinued intranasal study, where men dosed 45 minutes to 2 hours before activity at a much higher 10 mg intranasal dose, which is not comparable to a subcutaneous milligram figure because the route and bioavailability differ entirely (Diamond LE, et al., PubMed 18206919, retrieved 2026-06-15). In other words, there is no validated subcutaneous male dose at all, which is exactly why the off-label 1 to 2 mg range should be read as convention rather than evidence.

The detailed titration ladder, the dose-conversion math (mg to syringe units), reconstitution volumes, timing strategy, and injection-site choices are a dedicated spoke. We cover only the high-level framing here and link out to our peptide dosing calculator, the peptide reconstitution calculator, and the general peptide injections guide.

For orientation only, here is how the routes and figures are commonly described (not a recommendation):

Our take: PT-141 is unusual because there is an actual approved label to anchor a dose, which most research peptides lack. Use that as the reference point. When you see online protocols pushing well above ~2 mg, remember the approved dose is 1.75 mg and that the trade-off for more is mostly more nausea, not more effect.

How fast does PT-141 work and how long does it last?

Based on the approved label, PT-141 is taken on-demand at least 45 minutes before activity; pharmacology data show blood levels peak around one hour after a subcutaneous injection and the drug clears quickly, with a short half-life, so the practical window is a few hours rather than all day. This is pharmacodynamics from the FDA label, not a dosing recommendation. The on-demand design is the whole point: PT-141 is a "before activity" drug, not a daily one.

The numbers come straight from the Vyleesi clinical-pharmacology data. After a single 1.75 mg subcutaneous dose, bremelanotide reaches its median peak concentration (Tmax) at about 1.0 hour (range 0.5 to 1.0 hour) and has a mean terminal half-life of roughly 2.7 hours (range 1.9 to 4.0 hours), with essentially complete (~100%) bioavailability and no meaningful difference between abdomen and thigh injection sites (FDA, "VYLEESI Prescribing Information", 2019, retrieved 2026-06-15). That short half-life is why the label instructs taking it at least 45 minutes before anticipated sexual activity, and why the felt window is measured in hours, not a full day. The same pharmacokinetics shape the safety timing: the transient rise in blood pressure and small drop in heart rate after each dose usually return to baseline within about 12 hours, and as long as no more than one dose is taken in 24 hours, the label does not expect cumulative blood-pressure effects (DailyMed / FDA, "VYLEESI label", 2019, retrieved 2026-06-15).

On monitoring, the single most important gate is cardiovascular. Because each dose transiently raises blood pressure, the label restricts use to people without uncontrolled hypertension or known cardiovascular disease, which in practice means a clinician should check blood pressure and heart history before use. Two timing cues are worth remembering: the nausea that drives most discontinuations tends to peak one to two hours after the dose, overlapping the concentration peak, and the blood-pressure effect is over within about half a day.

Our take: Treat PT-141 like an on-demand tool with a short runway: dose it ahead of time, expect a window of a few hours, and do not stack doses to "extend" it, because more frequent dosing mainly adds nausea and blood-pressure load, not more benefit. The deeper timing-strategy and titration math lives in our peptide dosing calculator.

What are the side effects of PT-141?

PT-141's most common side effect by far is nausea, followed by flushing and headache; the most important safety concern is a transient rise in blood pressure, which is why it is not for people with uncontrolled hypertension or heart disease. These are well documented because, unlike most peptides, PT-141 went through full trials and has an FDA label.

In the RECONNECT trials, nausea occurred in about 40% of women on bremelanotide versus 1.3% on placebo, flushing in roughly 20% versus 0.3%, and headache in about 11% versus 1.9%; the nausea was usually mild to moderate, peaked one to two hours after the dose, and only about 8% of women discontinued because of it (American Journal of Obstetrics & Gynecology / PMC, 2022, retrieved 2026-06-15). The label also notes injection-site reactions and vomiting among common adverse reactions, and a transient increase in blood pressure with a small decrease in heart rate after each dose, which is the basis for its cardiovascular cautions (FDA, "VYLEESI Prescribing Information", 2019, retrieved 2026-06-15).

A hub-level overview of what is reported:

• Very common: nausea (about 40% in trials), usually within an hour or two of dosing.
• Common: flushing (~20%), headache (~11%), injection-site reactions, vomiting.
• Cardiovascular: a transient rise in blood pressure and small drop in heart rate after each dose; the reason it is contraindicated in uncontrolled high blood pressure or known cardiovascular disease.
• Cosmetic / pigment: focal hyperpigmentation (patchy skin or gum darkening), more likely with daily use or in people with darker skin, from PT-141's weak MC1R activity.
• Quality-related (off-label vials): because grey-market "research" vials are not the approved product, contamination, wrong potency, and non-sterile product are real, separate risks.

Two interaction points are worth flagging at the hub level because they surprise people. First, alcohol: unlike flibanserin (Addyi), which carries an alcohol warning, the Vyleesi label states that bremelanotide does not interact with alcohol, so alcohol is not a listed contraindication (DailyMed / FDA, "VYLEESI label", 2019, retrieved 2026-06-15). Second, oral drug absorption: because bremelanotide slows gastric emptying, it can reduce the rate and extent of absorption of some oral medications, and the label specifically warns against using it alongside an oral naltrexone-containing product taken for alcohol or opioid dependence, since lower naltrexone levels could lead to treatment failure (DailyMed / FDA, 2019, retrieved 2026-06-15). Neither of these is dosing advice, they are reasons to review your full medication list with a clinician before use.

This is the hub-level summary. A full side-effect deep-dive, including how to time doses around nausea, the blood-pressure detail, and the hyperpigmentation question, is a dedicated spoke: PT-141 side effects and safety deep-dive.

How does PT-141 compare to Viagra and Melanotan 2?

PT-141 differs from Viagra and Cialis because it acts on sexual desire in the brain rather than on blood flow, and it differs from Melanotan 2 because, although they come from the same peptide family, PT-141 targets the brain's sexual circuits while Melanotan 2 targets skin pigment. Understanding these two comparisons clears up most of the confusion around PT-141.

Versus PDE5 inhibitors (Viagra, Cialis): those drugs improve blood flow to the genitals but do nothing for desire, so they fail when the problem is wanting sex rather than the physical response. PT-141 works on desire itself, which is why it is sometimes used off-label when Viagra-type drugs alone have not worked, and why a combination is being studied in men (Urology Times, 2024, retrieved 2026-06-15). Versus Melanotan 2: PT-141 is literally an active metabolite of Melanotan 2 with one chemical group removed, which is why Melanotan 2 users often notice libido and erection effects, that is the same MC4R activity PT-141 was developed to target (Wikipedia, "Bremelanotide", retrieved 2026-06-15). The difference is emphasis: Melanotan 2 strongly hits the skin's MC1R (tanning), while PT-141 mostly hits MC4R (desire).

The full side-by-side, including dosing differences, onset and duration, and when each is chosen, builds on the mechanism contrast above. For where PT-141 sits among the alternatives, see our best peptides for libido roundup and our melanotan-2 complete guide.

Is PT-141 safe and legal?

PT-141 has a layered legal status: as the approved drug Vyleesi it is legal by prescription for HSDD in premenopausal women, but the injectable "research peptide" vials sold online are unapproved, off-label use (including all use in men) is not FDA-reviewed, and compounded versions are not the approved product. "Approved" applies to a narrow lane, not to PT-141 in general.

On safety, PT-141 is better characterized than most peptides because it has a full FDA label, which is genuinely reassuring for the approved use, but that label also carries real cautions: it should not be used by people with uncontrolled hypertension or known cardiovascular disease because of the transient blood-pressure increase after each dose (FDA, "VYLEESI Prescribing Information", 2019, retrieved 2026-06-15). On legality, the key distinction is the product: the approved Vyleesi injection is a legal prescription medicine, while compounded PT-141 is only appropriate when a prescriber documents a patient-specific clinical need for something different from the approved product, and the lyophilized vials sold "for research use only" online are unapproved and outside that framework (Telehealth Ally, "PT-141 Bremelanotide Guide 2026", 2026, retrieved 2026-06-15). For the full legal picture and how to evaluate a vendor, see are peptides legal and how to vet peptide quality.

Our take: PT-141's approval is a double-edged thing. It is real evidence that the compound works and is reasonably safe for one use, which sets it apart from research-only peptides. But that approval is for women, at a set dose, as a prescription product, and people routinely stretch it to cover men, higher doses, and grey-market vials, none of which the approval actually backs. Treat "FDA-approved" as a precise statement, not a blanket endorsement.

How do people obtain PT-141?

People access PT-141 in three main ways: a prescription for the approved Vyleesi product, compounded PT-141 through a licensed pharmacy on a prescription (often via telehealth), or unapproved "research chemical" vials bought online, which is the riskiest route. Only the first two involve a clinician and a regulated supply chain.

The cleanest path is a prescription for Vyleesi from a clinician, which is the FDA-approved product. Beyond that, many people obtain compounded PT-141 through telehealth providers and 503A compounding pharmacies, which can be legitimate when a prescriber documents a clinical reason, but compounded product is not the FDA-approved drug and has not been reviewed for safety or efficacy (Telehealth Ally, 2026, retrieved 2026-06-15). The third route, lyophilized vials sold "for research use only" online, is where most off-label searches end up; that market carries real risks of mislabeled potency, impurities, and non-sterile product, with no regulatory oversight.

If you are considering PT-141, the responsible groundwork is:

1. Talk to a qualified clinician first, ideally one who can screen your blood pressure and heart history, since the cardiovascular caution is the main safety gate.
2. Prefer the approved or properly prescribed route. A Vyleesi prescription, or pharmacist-compounded product on a real prescription, is a different risk category from a grey-market vial.
3. Confirm the legal status for your country and situation, including off-label rules. See are peptides legal.
4. If using any non-approved vial, demand a certificate of analysis (COA) from independent third-party testing, and learn to read it for identity and purity. See how to vet peptide quality.
5. Understand handling. Reconstitution and cold storage are not optional. See getting started with peptides and the peptide injections guide.

We are describing what people do, not endorsing any particular route. The approved product exists for a reason; stepping outside it means accepting less oversight.

What results can you realistically expect?

For the approved use, the realistic expectation is a modest but real improvement in sexual desire and a reduction in the distress low desire causes, not a dramatic on-demand "switch"; for off-label use, expectations should be more cautious because the evidence is thinner. Calibrated expectations matter as much here as with any sexual-health treatment.

In the trials, the benefit in women was statistically significant on both desire and distress, but it was a meaningful average improvement rather than a transformation for everyone, and a sizable share of people did not respond (American Journal of Obstetrics & Gynecology / PMC, 2022, retrieved 2026-06-15). To put the size of that effect in concrete terms: the desire gain averaged about a third of a point on the FSFI-D scale, with the more clinically useful signal being the paired reduction in desire-related distress (Kingsberg SA, et al., Obstetrics & Gynecology, 2019, PubMed 31599840, retrieved 2026-06-15). That is the realistic frame: a real nudge in interest and a real drop in the distress low desire causes, for a subset of women, not a guaranteed on-demand switch.

Because PT-141 acts on desire, the felt effect is often described as increased interest and arousal rather than a purely mechanical one, and it is taken on-demand, with effects beginning roughly when blood levels peak around an hour after dosing and tapering over the next few hours as the short half-life clears it. Three honest caveats: first, individual response varies a lot, and the nausea trade-off is real, in the trials nausea was the single most common reason women stopped; second, response is not predictable in advance, so people typically learn over a few on-demand doses whether they are responders; third, for off-label uses like men's ED or libido, the evidence is earlier and the response harder to predict still. A useful way to set expectations is to think of PT-141 as a desire amplifier with a ceiling, not a performance drug, it raises wanting, it does not manufacture a physical response on its own the way a blood-flow drug aims to. For grounded before-and-after context and how to read transformation claims, see peptides before and after.

Frequently Asked Questions

The bottom line

PT-141 is the rare peptide that bridges two worlds. On one side, it is a genuine FDA-approved medicine: as Vyleesi, backed by two Phase 3 trials, it treats low sexual desire in premenopausal women by acting on the brain's desire circuitry rather than on blood flow. That approval is real evidence that the mechanism works and that the compound is reasonably safe for that specific use, which puts PT-141 in a different category from research-only peptides.

The other half of the story is discipline about what "approved" actually covers. The approval is for women, at a 1.75 mg on-demand dose, as a prescription product, and people routinely stretch it to men, higher doses, and unregulated "research" vials, none of which that approval backs. The side effects, especially nausea, are common, and the transient blood-pressure effect is a real cardiovascular gate. If you take one thing from this hub, let it be the precision of the status: PT-141 is approved for one use, promising-but-unproven for others, and safest when a clinician is involved. From here, the natural next reads are our melanotan-2 complete guide, are peptides legal, and how to vet peptide quality.

Sources

• U.S. Food and Drug Administration. "VYLEESI (bremelanotide injection) Prescribing Information." Initial U.S. Approval 2019. Retrieved 2026-06-15. https://www.accessdata.fda.gov/spl/data/3dca0cf9-a278-4c25-af93-d65f1f523504/3dca0cf9-a278-4c25-af93-d65f1f523504.xml
• Wikipedia. "Bremelanotide." Retrieved 2026-06-15. https://en.wikipedia.org/wiki/Bremelanotide
• "Bremelanotide for Treatment of Female Hypoactive Sexual Desire." American Journal of Obstetrics & Gynecology / PMC, 2022. Retrieved 2026-06-15. https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/
• Kingsberg, S.A., et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials." Obstetrics & Gynecology, 2019. PubMed 31599840. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/31599840/
• Simon, J.A., Kingsberg, S.A., et al. "Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder." Obstetrics & Gynecology, 2019. Retrieved 2026-06-15. https://journals.lww.com/greenjournal/fulltext/2019/11000/long_term_safety_and_efficacy_of_bremelanotide_for.3.aspx
• Diamond, L.E., Earle, D.C., Rosen, R.C., et al. "Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study." PubMed 18206919. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/18206919/
• DailyMed / U.S. Food and Drug Administration. "Label: VYLEESI- bremelanotide injection." 2019. Retrieved 2026-06-15. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9
• Palatin Technologies. "FDA Approves New Drug Application for Vyleesi (bremelanotide injection)." 2019. Retrieved 2026-06-15. https://palatin.com/press_releases/fda-approves-new-drug-application-for-vyleesi-bremelanotide-injection-2/
• Urology Times. "Phase 2 study launches of bremelanotide plus a PDE5 inhibitor for erectile dysfunction." 2024. Retrieved 2026-06-15. https://www.urologytimes.com/view/phase-2-study-launches-of-bremelanotide-plus-a-pde5-inhibitor-for-erectile-dysfunction
• Telehealth Ally. "PT-141 Bremelanotide Guide 2026: Evidence, FDA Status, Dosing & Providers." 2026. Retrieved 2026-06-15. https://www.telehealthally.com/guides/pt-141-bremelanotide-guide
• Swolverine. "PT-141 (Bremelanotide): Benefits, Dosage, Side Effects, and Safety." Retrieved 2026-06-15. https://swolverine.com/blogs/blog/pt-141-bremelanotide-benefits-dosage-side-effects-and-safety
• PubChem. "Bremelanotide (CID 9941379)." Retrieved 2026-06-15. https://pubchem.ncbi.nlm.nih.gov/compound/9941379